The PharmaTimes article, written by MarieElena Cordisco, MA, NP-C, APRN, Senior Director, Therapeutic Strategy Lead, Metabolic, highlights a significant rebound effect when patients discontinue GLP-1 agonists, including weight regain and increased cardiometabolic risks. It emphasizes the need for clinical trial sponsors and researchers to proactively address these issues by educating staff and participants, combating obesity bias, and providing continuous support to ensure patients feel valued and informed throughout the study.
Read the full article here.
